Researchers from Universite de Sherbrooke and University of California San Francisco presented the discovery and preclinical characterization of CCR2-targeting pepducin, PP-101.
Researchers from Shandong University and affiliated organizations reported the discovery and preclinical characterization of novel 68Ga-labeled PSMA-targeting tracers for the diagnosis of prostate cancer.
Researchers from BC Cancer Research Institute (Provincial Health Services Authority) and the University of British Columbia have presented the discovery and preclinical characterization of [68Ga]LW-02050, a 68Ga-labeled hydroxamate derivative of SB3.
Atomwise Inc. reported the development and preclinical evaluation data of ATMW-DC, a novel orally available allosteric inhibitor of TYK2 developed using Atomwise’s drug discovery platform Atomnet, for the potential treatment of psoriatic inflammation.
Rgenta Therapeutics Inc. has presented their work on the discovery and development of RGT-61159, a potential first-in-class oral inhibitor of the oncogenic transcription factor c-MYB.
Septerna Inc. scientists have reported proof-of-concept data on a novel oral small-molecule thyroid-stimulating hormone receptor (TSHR) antagonist, SP-1351, with potential for the treatment of Graves’ disease (GD), including ophthalmic manifestations.
At last week’s EASL meeting, Janssen Pharmaceutica NV disclosed the discovery and preclinical evaluation of a novel pan-genotypic hepatitis E virus (HEV) replication inhibitor, JNJ-64779117 (JNJ-9117).
Chengdu Easton Biopharmaceuticals Co. Ltd. recently presented findings that highlight the potential anticancer agent D0112-005 as a potent and selective poly (ADP-ribose) polymerase 1 (PARP-1) inhibitor with excellent antitumor efficacy and a good safety profile in vivo.
In metabolic dysfunction-associated steatohepatitis (MASH) preclinical models, absence of the lipid droplet-associated protein hydroxysteroid 17β dehydrogenase 13 (17β-HSD13) has been identified as protective against liver fibrosis.
RSS
